Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

PURPOSE: Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy in patients with CML-AP who have experienced treatment failure...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Apperley, Jane F., Cortes, Jorge E., Kim, Dong-Wook, Roy, Lydia, Roboz, Gail J., Rosti, Gianantonio, Bullorsky, Eduardo O., Abruzzese, Elisabetta, Hochhaus, Andreas, Heim, Dominik, de Souza, Carmino A., Larson, Richard A., Lipton, Jeffrey H., Khoury, H. Jean, Kim, Hyeoung-Joon, Sillaber, Christian, Hughes, Timothy P., Erben, Philipp, Van Tornout, Jan, Stone, Richard M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2009
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979080/
https://ncbi.nlm.nih.gov/pubmed/19487385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.14.3339
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars